The Latin America, Middle East and Africa Pigmentation Disorder Treatment Market would witness market growth of 6.9% CAGR during the forecast period (2023-2030).
The rising incidence of pigmentation disorders, such as melasma, post-inflammatory hyperpigmentation, and age-related skin discoloration, has boosted the demand for effective treatment options. As the population ages, there is a higher demand for anti-aging and skin rejuvenation treatments, often including pigmentation disorder treatments.
Heightened awareness of the effects of sun exposure and pollution on skin health has led more individuals to seek treatment for pigmentation issues. Continued advancements in dermatological technology, including laser therapies, chemical peels, and topical treatments, have made pigmentation disorder treatments more effective and accessible. Aesthetic concerns drive many individuals to seek treatments that improve skin tone and appearance, contributing to the market's growth.
As per National Library of Medicine (NIH), in the Middle East, many patients with darker pigmentation (Fitzgerald skin types III-VI) are prone to develop post-inflammatory hyperpigmentation (PIH) due to acne. According to NIH, pigmentary disorders are among the top five most prevalent dermatological diagnoses among people of African descent. Dyschromias are the third most frequent dermatological diagnosis in Durban, KwaZulu-Natal, South Africa. In order of frequency, vitiligo, post-inflammatory hyperpigmentation, and melasma are the most prevalent subtypes of pigmentary disorders. Vitiligo, post inflammatory hyperpigmentation, and melasma are the three most prevalent pigmentary diagnoses among the 304 patients, mostly African women. Skin health awareness continues to grow in the LAMEA region, and the market is likely to expand further.
The Brazil market dominated the LAMEA Pigmentation Disorder Treatment Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $19.7 million by 2030. The Argentina market is showcasing a CAGR of 7.4% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 6.6% during (2023 - 2030).
Based on Type, the market is segmented into Vitiligo, Melasma, and Others. Based on Treatment, the market is segmented into Corticosteroids, Calcineurin Inhibitor, and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies, & Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Bausch Health Companies Inc, Glenmark Pharmaceuticals Limited, Obagi Cosmeceuticals LLC, AbbVie, Inc., Dermavant Sciences, Inc. (Roivant Sciences Ltd.), Incyte Corporation, Dr. Reddy’s Laboratories Ltd., Galderma S.A., Viatris, Inc. (Mylan N.V.), and Pfizer, Inc.
The rising incidence of pigmentation disorders, such as melasma, post-inflammatory hyperpigmentation, and age-related skin discoloration, has boosted the demand for effective treatment options. As the population ages, there is a higher demand for anti-aging and skin rejuvenation treatments, often including pigmentation disorder treatments.
Heightened awareness of the effects of sun exposure and pollution on skin health has led more individuals to seek treatment for pigmentation issues. Continued advancements in dermatological technology, including laser therapies, chemical peels, and topical treatments, have made pigmentation disorder treatments more effective and accessible. Aesthetic concerns drive many individuals to seek treatments that improve skin tone and appearance, contributing to the market's growth.
As per National Library of Medicine (NIH), in the Middle East, many patients with darker pigmentation (Fitzgerald skin types III-VI) are prone to develop post-inflammatory hyperpigmentation (PIH) due to acne. According to NIH, pigmentary disorders are among the top five most prevalent dermatological diagnoses among people of African descent. Dyschromias are the third most frequent dermatological diagnosis in Durban, KwaZulu-Natal, South Africa. In order of frequency, vitiligo, post-inflammatory hyperpigmentation, and melasma are the most prevalent subtypes of pigmentary disorders. Vitiligo, post inflammatory hyperpigmentation, and melasma are the three most prevalent pigmentary diagnoses among the 304 patients, mostly African women. Skin health awareness continues to grow in the LAMEA region, and the market is likely to expand further.
The Brazil market dominated the LAMEA Pigmentation Disorder Treatment Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $19.7 million by 2030. The Argentina market is showcasing a CAGR of 7.4% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 6.6% during (2023 - 2030).
Based on Type, the market is segmented into Vitiligo, Melasma, and Others. Based on Treatment, the market is segmented into Corticosteroids, Calcineurin Inhibitor, and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies, & Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Bausch Health Companies Inc, Glenmark Pharmaceuticals Limited, Obagi Cosmeceuticals LLC, AbbVie, Inc., Dermavant Sciences, Inc. (Roivant Sciences Ltd.), Incyte Corporation, Dr. Reddy’s Laboratories Ltd., Galderma S.A., Viatris, Inc. (Mylan N.V.), and Pfizer, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type- Vitiligo
- Melasma
- Others
- Corticosteroids
- Calcineurin Inhibitor
- Others
- Drug Store & Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Bausch Health Companies Inc
- Glenmark Pharmaceuticals Limited
- Obagi Cosmeceuticals LLC
- AbbVie, Inc.
- Dermavant Sciences, Inc. (Roivant Sciences Ltd.)
- Incyte Corporation
- Dr.Reddy’s Laboratories Ltd.
- Galderma S.A.
- Viatris, Inc. (Mylan N.V.)
- Pfizer, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA Pigmentation Disorder Treatment Market, By Type
Chapter 5. LAMEA Pigmentation Disorder Treatment Market, By Treatment
Chapter 6. LAMEA Pigmentation Disorder Treatment Market, By Distribution Channel
Chapter 7. LAMEA Pigmentation Disorder Treatment Market, By Country
Chapter 8. Company Profiles
Companies Mentioned
- Bausch Health Companies Inc
- Glenmark Pharmaceuticals Limited
- Obagi Cosmeceuticals LLC
- AbbVie, Inc.
- Dermavant Sciences, Inc. (Roivant Sciences Ltd.)
- Incyte Corporation
- Dr. Reddy’s Laboratories Ltd.
- Galderma S.A.
- Viatris, Inc. (Mylan N.V.)
- Pfizer, Inc.
Methodology
LOADING...
